Bedrocan Canada and Tweed announce multi-centre longitudinal surveillance study of medical cannabis patients

Warning message

The subscription service is currently unavailable. Please try again later.

Bedrocan Canada and its sister company Tweed just announced the launch of the EQUAL (Evaluation QUAlity of Life) study. The clinical research initiative is a multi-centre, non-interventional, un-blinded study to evaluate quality of life in Canadian patients treated with medical cannabis. The company-sponsored study will evaluate patients who use Bedrocan and Tweed strains of cannabis to help manage symptoms of a range of chronic health conditions, and the resulting data will be submitted for publication by a peer-reviewed medical journal. To ensure patient privacy, all data collected will be anonymized and stored in a secure electronic database.

The primary objective of the study, which is intended to continue for three years, include more than 50 sites, and enroll up to 6,000 patients, is to evaluate the quality of life (QoL) of patients before and after treatment with medical cannabis. The study will use a well-established general QoL assessment instrument, the SF-36, and...

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.